WO2002053142A3 - Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines - Google Patents

Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines Download PDF

Info

Publication number
WO2002053142A3
WO2002053142A3 PCT/US2002/000036 US0200036W WO02053142A3 WO 2002053142 A3 WO2002053142 A3 WO 2002053142A3 US 0200036 W US0200036 W US 0200036W WO 02053142 A3 WO02053142 A3 WO 02053142A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
cytokines
administration
superoxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/000036
Other languages
French (fr)
Other versions
WO2002053142A2 (en
Inventor
Daniela Salvemini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metaphore Pharmaceuticals Inc
Original Assignee
Metaphore Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metaphore Pharmaceuticals Inc filed Critical Metaphore Pharmaceuticals Inc
Priority to AT02707393T priority Critical patent/ATE464061T1/en
Priority to EP02707393A priority patent/EP1347773B1/en
Priority to AU2002241807A priority patent/AU2002241807A1/en
Priority to DE60235955T priority patent/DE60235955D1/en
Priority to US10/433,290 priority patent/US20050175580A1/en
Priority to JP2002554093A priority patent/JP4331939B2/en
Publication of WO2002053142A2 publication Critical patent/WO2002053142A2/en
Publication of WO2002053142A3 publication Critical patent/WO2002053142A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to compositions which enhance a mammal's immune response to a cytokine by administering therapeutic amounts of catalysts for the dismutation of superoxide which include superoxide dismutase enzyme (SOD) and small molecular weight organic ligand mimics of that enzyme (SOD mimetics or SODms), alone or in combination with a cytokine. These compositions may be used in methods for enhancing a mammal's immune response to a virus such as the hepatitis C virus or the human immunodeficiency virus (HIV) or to a tumor thereby inhibiting the proliferation of the tumor. Relatedly, these compositions may be used in methods of treating mammals infected with HIV or mammals suffering from Hepatitis C or AIDS. This invention also relates to methods of enhancing cancer therapy and methods of preventing and treating hypotension in a mammal resulting from the administration of cytokines by the administration of therapeutic amounts of catalysts for the dismutation of superoxide in combination with a cytokine and catecholamine pressor agents. Also provided are pharmaceutical compositions comprising catalysts for the dismutation of superoxide alone or in combination with cytokines and catecholamine pressor agents for use in the above methods.
PCT/US2002/000036 2001-01-05 2002-01-03 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines Ceased WO2002053142A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT02707393T ATE464061T1 (en) 2001-01-05 2002-01-03 COMPOSITIONS AND METHODS FOR INCREASE CYTOKINE ACTIVITY AND FOR TREATING HYPOTENSION ASSOCIATED WITH THE ADMINISTRATION OF CYTOKINES
EP02707393A EP1347773B1 (en) 2001-01-05 2002-01-03 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
AU2002241807A AU2002241807A1 (en) 2001-01-05 2002-01-03 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
DE60235955T DE60235955D1 (en) 2001-01-05 2002-01-03 COMPOSITIONS AND METHODS FOR INCREASING CYTOKINE ACTIVITY AND TREATING THE HYPOTENSION ASSOCIATED WITH THE ADMINISTRATION OF CYTOKINES
US10/433,290 US20050175580A1 (en) 2001-01-05 2002-01-03 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
JP2002554093A JP4331939B2 (en) 2001-01-05 2002-01-03 Compositions and methods for enhancing cytokine activity and treating hypotension associated with cytokine administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26012001P 2001-01-05 2001-01-05
US60/260,120 2001-01-05

Publications (2)

Publication Number Publication Date
WO2002053142A2 WO2002053142A2 (en) 2002-07-11
WO2002053142A3 true WO2002053142A3 (en) 2002-12-27

Family

ID=22987847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000036 Ceased WO2002053142A2 (en) 2001-01-05 2002-01-03 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines

Country Status (7)

Country Link
US (1) US20050175580A1 (en)
EP (1) EP1347773B1 (en)
JP (1) JP4331939B2 (en)
AT (1) ATE464061T1 (en)
AU (1) AU2002241807A1 (en)
DE (1) DE60235955D1 (en)
WO (1) WO2002053142A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2725023T3 (en) 2006-10-12 2019-09-18 Galera Labs Llc Methods for the treatment of oral mucositis
US20110009416A1 (en) * 2009-07-07 2011-01-13 Sepracor Inc. PH INDEPENDENT FORMULATIONS OF 6-(5-CHLORO-2-PYRIDYL)-5-[(4-METHYL-1-PIPERAZINYL)CARBONYLOXY]-7-OXO-6,7-DIHYDRO-5H-PYRROLO[3,4-b]PYRAZINE
EP2760874A4 (en) * 2011-09-26 2015-04-08 Galera Therapeutics Llc METHODS OF TREATING DISEASES
RS60558B1 (en) 2015-08-11 2020-08-31 Galera Labs Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
KR20180132939A (en) 2016-05-03 2018-12-12 갈레라 랩스, 엘엘씨 Combination therapy for cancer treatment
JP7166634B2 (en) 2016-09-01 2022-11-08 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー Combination Cancer Therapy with Pentaaza Macrocycle Conjugates and Ascorbic Acid Compounds
IL295620B2 (en) 2017-04-13 2024-01-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011277A2 (en) * 1988-05-23 1989-11-30 Georgia State University Foundation, Inc. Porphyrin and phthalocyanine antiviral compositions
WO1997033588A1 (en) * 1996-03-13 1997-09-18 Monsanto Company Iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2265387A (en) * 1940-03-11 1941-12-09 John H Mcmillin Nasal pack
US2493326A (en) * 1949-03-01 1950-01-03 John H Trinder Tampon for control of intractable nasal hemorrhages
US2847997A (en) * 1956-01-13 1958-08-19 James J Tibone Catheter
US3049125A (en) * 1960-03-28 1962-08-14 Kriwkowitsch George Nose packing device
US3420237A (en) * 1966-09-02 1969-01-07 Martha K Fortay Process and article for the treatment of severe epistaxis
GB1340788A (en) * 1971-02-04 1974-01-30 Matburn Holdings Ltd Nasal tampons
US4044793A (en) * 1975-08-25 1977-08-30 Shiley Laboratories, Inc. Relief valve
US4338941A (en) * 1980-09-10 1982-07-13 Payton Hugh W Apparatus for arresting posterior nosebleeds
US4364392A (en) * 1980-12-04 1982-12-21 Wisconsin Alumni Research Foundation Detachable balloon catheter
US4638803A (en) * 1982-09-30 1987-01-27 Rand Robert W Medical apparatus for inducing scar tissue formation in a body
US4619261A (en) * 1984-08-09 1986-10-28 Frederico Guerriero Hydrostatic pressure device for bleeding control through an inflatable, stitchable and retrievable balloon-net system
US5248603A (en) * 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
US4832680A (en) * 1986-07-03 1989-05-23 C.R. Bard, Inc. Apparatus for hypodermically implanting a genitourinary prosthesis
US4686962A (en) * 1986-07-03 1987-08-18 Habley Medical Technology Corporation Disposable cartridge assembly for hypodermically implanting a genitourinary prosthesis
US4883465A (en) * 1988-05-24 1989-11-28 Brennan H George Nasal tampon and method for using
US5224497A (en) * 1988-07-06 1993-07-06 Ehlers Robert L Method of removing diverticula in the colon
US4950280A (en) * 1988-08-02 1990-08-21 Brennan H George Nasal tampon having a counter weight
US5100385A (en) * 1989-01-27 1992-03-31 C. R. Bard, Inc. Fast purge balloon dilatation catheter
DE69023515T2 (en) * 1989-06-28 1996-04-04 David S Zimmon INFLATABLE TAMPONADE DEVICES.
US5061274A (en) * 1989-12-04 1991-10-29 Kensey Nash Corporation Plug device for sealing openings and method of use
CA2072934C (en) * 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5334380A (en) * 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US5176692A (en) * 1991-12-09 1993-01-05 Wilk Peter J Method and surgical instrument for repairing hernia
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5545721A (en) * 1992-12-21 1996-08-13 Ophidian Pharmaceuticals, Inc. Conjugates for the prevention and treatment of sepsis
US5312435A (en) * 1993-05-17 1994-05-17 Kensey Nash Corporation Fail predictable, reinforced anchor for hemostatic puncture closure
US5486195A (en) * 1993-07-26 1996-01-23 Myers; Gene Method and apparatus for arteriotomy closure
TW252045B (en) * 1993-10-07 1995-07-21 Allan L Goldstein
US5545176A (en) * 1994-05-31 1996-08-13 Murtfeldt; Robert L. Wound dilatation device
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5645566A (en) * 1995-09-15 1997-07-08 Sub Q Inc. Apparatus and method for percutaneous sealing of blood vessel punctures
US5707355A (en) * 1995-11-15 1998-01-13 Zimmon Science Corporation Apparatus and method for the treatment of esophageal varices and mucosal neoplasms
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011277A2 (en) * 1988-05-23 1989-11-30 Georgia State University Foundation, Inc. Porphyrin and phthalocyanine antiviral compositions
WO1997033588A1 (en) * 1996-03-13 1997-09-18 Monsanto Company Iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
K.I. TODA E.A.: "UVB/PUVA-induced suppression of human natural killer activity is reduced by superoxide dismutase and /or interleukin 2 in vitro", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 86, no. 5, 1986, pages 519 - 522, XP008009802 *
W.E.SAMLOWSKI E.A.: "The SOD mimetic M40403 blocks IL-2 induced hypotension and increases anticancer responses", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 42, 2001, pages 502, XP008009749 *

Also Published As

Publication number Publication date
JP4331939B2 (en) 2009-09-16
JP2004517113A (en) 2004-06-10
AU2002241807A1 (en) 2002-07-16
DE60235955D1 (en) 2010-05-27
EP1347773B1 (en) 2010-04-14
WO2002053142A2 (en) 2002-07-11
ATE464061T1 (en) 2010-04-15
EP1347773A2 (en) 2003-10-01
US20050175580A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
ES2207830T3 (en) ALFA POLYETHYLENGLYCOL INTERFERON CONJUGATES FOR INFECTION THErapy.
PL372294A1 (en) Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
BRPI0414045A (en) administration of tlr7 ligands and prodrugs thereof for the treatment of hepatitis C virus infection
MY141594A (en) 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
KR20050055053A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
CA2580448A1 (en) Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin
WO2001016330A3 (en) Prevention of affections associated with porcine circovirus-2
WO2001066123A3 (en) Composition consisting of phy906 and chemotherapeutic agents
WO2005105213A3 (en) Indole and azaindole derivatives with antitumor action
WO2006110655A3 (en) Compounds, compositions and methods for the treatment of poxvirus infections
WO2001023414A3 (en) Immunologically significant herpes simplex virus antigens
WO2000066141A3 (en) Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
EP1392328A4 (en) ANTICANCER THERAPY
WO2002053142A3 (en) Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
WO2002072027A3 (en) Oncolytic rna replicons
Bullard et al. Comparison of intravenous versus intracarotid therapy with 1, 3-bis (2-chloroethyl)-1-nitrosourea in a rat brain tumor model
Baumann et al. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping
IL316160A (en) Treatment of arginase 1 deficiency
WO2003002528A3 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
EA200700433A1 (en) BETULINOL DERIVATIVES AS AN AGENTS AGAINST HIV (HUMAN IMMUNE DEFICIENCY VIRUS)
WO2003072061A3 (en) Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy
Pluta et al. The use of interferon in medicine
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
WO2002089828A3 (en) Interferons in the treatment of ischemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002554093

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002707393

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002707393

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10433290

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 200403070

Country of ref document: ZA